Background:
Uncontrolled cell growth and proliferation, which originate from lung tissue
often lead to lung carcinoma and are more likely due to smoking as well as inhaled environmental
toxins. It is widely recognized that tumour cells evade the ability of natural programmed death
(apoptosis) and facilitates tumour progression and metastasis. Therefore investigating and targeting
the apoptosis pathway is being utilized as one of the best approaches for decades.
Objective:
This review describes the emergence of SMAC mimetic drugs as a treatment approach,
its possibilities to synergize the response along with current limitations as well as future perspective
therapy for lung cancer.
Method:
Articles were analysed using search engines and databases namely Pubmed and Scopus.
Result:
Under cancerous circumstances, the level of Inhibitor of Apoptosis Proteins (IAPs) gets elevated,
which suppresses the pathway of programmed cell death, plus supports the proliferation of
lung cancer. As it is a major apoptosis regulator, natural drugs that imitate the IAP antagonistic response
like SMAC mimetic agents/Diablo have been identified to trigger cell death. SMAC i.e. second
mitochondria activators of caspases is a molecule produced by mitochondria, stimulates apoptosis
by neutralizing/inhibiting IAP and prevents its potential responsible for the activation of caspases.
Various preclinical data have proven that these agents elicit the death of lung tumour cells.
Apart from inducing apoptosis, these also sensitize the cancer cells toward other effective anticancer
approaches like chemo, radio, or immunotherapies. There are many SMAC mimetic agents such as
birinapant, BV-6, LCL161, and JP 1201, which have been identified for diagnosis as well as treatment
purposes in lung cancer and are also under clinical investigation.
Conclusion:
SMAC mimetics acts in a restorative way in the prevention of lung cancer.